ASCO/ASH Guideline Preserves Higher ESA Dosing Options For Cancer Patients
Executive Summary
Despite the emergence of safety concerns related to use of erythropoiesis-stimulating agents in recent years, the American Society of Hematology and the American Society of Clinical Oncology are essentially providing the same dosing recommendations in their latest guideline for treatment of chemotherapy-induced anemia as in the previous version from five years ago
You may also be interested in...
FDA Draws Upon New Authority To Mandate Elements OF ESA Labeling
FDA and the sponsors of erythropoiesis-stimulating agents were mostly able to reach an agreement on safety revisions to labeling of the anemia therapies, but the agency was forced to employ its new regulatory authority to resolve a couple points of continued disagreement
FDA Draws Upon New Authority To Mandate Elements OF ESA Labeling
FDA and the sponsors of erythropoiesis-stimulating agents were mostly able to reach an agreement on safety revisions to labeling of the anemia therapies, but the agency was forced to employ its new regulatory authority to resolve a couple points of continued disagreement
Amgen, J&J Propose New Target Range For Aranesp, Procrit
Just a year after FDA removed information related to a dosing target range for erythropoiesis-stimulating agents from product labeling, Amgen and Johnson & Johnson are proposing to re-establish a specific hemoglobin target range for the anemia therapies